Temozolomide followed by combined immunotherapy with GM-CSF, low-dose IL2 and IFNα in patients with metastatic melanoma
Open Access
- 28 January 2003
- journal article
- Published by Springer Nature in British Journal of Cancer
- Vol. 88 (2) , 175-180
- https://doi.org/10.1038/sj.bjc.6600717
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Effect of temozolomide on central nervous system relapse in patients with advanced melanomaMelanoma Research, 2002
- Factors Associated With Response to High-Dose Interleukin-2 in Patients With Metastatic MelanomaJournal of Clinical Oncology, 2001
- Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.2000
- Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant MelanomaJournal of Clinical Oncology, 2000
- Prognostic factors in metastatic melanomaCancer, 1993
- Temozolomide: A new oral cytotoxic chemotherapeutic agent with promising activity against primary brain tumoursEuropean Journal Of Cancer, 1993
- Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)British Journal of Cancer, 1992
- Constitutive expression of high affinity interleukin 2 receptors on human CD16-natural killer cells in vivo.The Journal of Experimental Medicine, 1990
- Functional consequences of interleukin 2 receptor expression on resting human lymphocytes. Identification of a novel natural killer cell subset with high affinity receptors.The Journal of Experimental Medicine, 1990
- Malignant melanoma and central nervous system metastases.Incidence, diagnosis, treatment and survivalCancer, 1978